Avexa Limited : Avexa files to extend ATC patent life
01/10/2012 | 10:25pm
Avexa Limited
ABN 53 108 150 750
576 Swan Street Richmond
Victoria Australia 3121
Telephone 61 3 9208 4300
Facsimile 61 3 9208 4146
Website www.avexa.com.au
Company announcement
Avexa files to extend ATC patent life
Melbourne, Australia - 23rd November 2011 -
Melbourne-based biotechnology company Avexa Limited
[ASX:AVX] today announced that it has filed two new patents
covering the company's Apricitabine (ATC) program. The two
patents are based around the clinical findings identified by
the company following the full analysis of the Phase II/III
data set.
Dr Jonathan Coates, Avexa's Interim Chief Executive Officer
and Chief Scientific Officer, said: "These patents have real
commercial application as they are focused on the use of ATC
and its synergistic benefits when taken with either of two
existing marketed drugs. These new patents dramatically
improve the IP position for the company's ATC program".
The success in the treatment of HIV-1 infection by drug
combinations has been known for some time. The results of our
recent studies show that, unexpectedly, a number of marketed
drugs work better with ATC than would have been predicted
from historical knowledge, and considerably better than in
combination with lamivudine, (ViiV's anti-HIV agent also
known as 3TC).
The new filings will add to the existing patent portfolio for
ATC and could potentially provide patent protection for the
ATC program. The filings have only recently been submitted;
the company will continue to update shareholders on the
progress of these filings, as well as other activities around
the ATC program.
"The use of these new findings is one example of how Avexa is
working to add shareholder value and increase the potential
of the ATC program, while keeping expenditure under control,"
said Avexa's Chairman Mr Iain Kirkwood.
|
For more information:
|
|
|
Mr Iain Kirkwood Chairman Avexa Ph: +61 3 9208 4300
|
Dr Jonathan Coates Interim CEO & CSO Ph: +61 3 9208
4300
|
Richard Allen
Oxygen Financial Public Relations
Ph: + 61 3 9915 6341
|
About Avexa Limited
Avexa Limited (www.avexa.com.au) is a Melbourne-based
biotechnology company with a focus on discovery, development
and commercialisation of small molecules for the treatment of
infectious diseases. Avexa's key projects include
apricitabine (ATC) for the treatment of drug-resistant HIV,
an HIV integrase program and an antibiotic program for
antibiotic-resistant bacterial infections.
www.avexa.com.au
